DALLAS—Aerus, a global leader in surface and air purification solutions, announced that independent test results on their Hydroxyl Blaster with ActivePure Technology confirms that the product kills the SARS-CoV-2 virus on surfaces. The testing data conducted by independent Food and Drug Administration-compliant laboratory, MRIGlobal, established a 99.98 percent surface kill rate of live SARS-CoV-2 virus in seven hours. SARS-CoV-2 is the virus that causes COVID-19.
Aerus’ award-winning ActivePure Technology is scientifically proven to destroy microscopic pathogens and contaminants on surfaces and in the air and is available in over 70 Aerus products, including the Aerus Medical Guardian cleared by the FDA as a Class II Medical Device 510(k). The Aerus Hydroxyl Blaster with ActivePure Technology is an affordable, mobile, plug-and-purify air purifier that works on interior aerosolized pathogens and surface contaminants.
Controlled, independent laboratory studies have established the efficacy of ActivePure Technology in Aerus products including:
- 93 percent surface kill in three hours of live SARS-CoV-2, even when covered by a protective biofilm, with the Aerus Hydroxyl Blaster with ActivePure Technology;
- 98 percent surface kill in six hours of live SARS-CoV-2, even when covered by a protective biofilm, with the Aerus Hydroxyl Blaster with ActivePure Technology;
- 99.999 percent kill rate of airborne RNA viruses in just 30 minutes with the Aerus Medical Guardian with ActivePure Technology, an FDA 510(k) Cleared Class II Medical Device; and
- 99.9999 percent kill rate of airborne RNA viruses in 60 minutes with the Aerus Medical Guardian with ActivePure Technology.
“We have a technology demonstrated in independent lab studies to kill COVID-19 indoors and gets the world back to work, back to school and back to life in a safer manner. Our unit works in real time to destroy 99.98 percent of new COVID-19 viruses reintroduced to the space, after just seven hours of installation,” said Joe Urso, CEO of Aerus. “The efficacy of our data is consistent with our other previously reported RNA and DNA virus test data and confirms that ActivePure Technology used in our surface and air purification systems is the fastest-acting continuous solution available. We are beyond pleased to announce these COVID-19 disinfection results with our ActivePure Technology solutions.”
How ActivePure Technology is Different
Air purifiers generally fall into two categories: active or capture based. As the name suggests, ActivePure Technology is an active-based disinfection solution, which enables Aerus devices with ActivePure Technology to not only disinfect and purify the air but surfaces as well. Aerus’ patented technology uses free oxygen and water molecules and converts them into powerful oxidizers, known as ActivePure Molecules, that are released back into the room, filling the interior space. ActivePure Molecules continuously seek out and destroy the room’s pathogens and contaminants in real time, 24 hours a day.
Capture-based air purifiers do not work in real time and are only effective against the contaminants that are captured and killed through a HEPA filter, carbon or ultraviolet light. These units, by design, are only partially effective at reducing some of the airborne pathogens and are not effective at treating pathogens on surfaces. Other devices, such as bi-polar ionization, have questionable results as indicated by the Centers for Disease Control (CDC) and the American Society of Heating, Refrigerating and Air Conditioning Engineers (ASHRAE).
- Actively and continuously disinfects surfaces and air 24/7, minimizing contamination, recontamination and cross contamination in real time.
- Safe to use in occupied spaces.
- Works without chemicals or ozone and breaks down viral contaminants into harmless byproducts.
Aerus is awaiting final approval from the FDA for Emergency Use Authorization (EUA) for the Aerus Hydroxyl Blaster with ActivePure Technology for use in reducing SARS-CoV-2 surface pathogens. The results have also been submitted by Aerus to the FDA-equivalent Canadian and European Union regulators, requesting that they clear Aerus ActivePure devices to combat the SARS-Cov-2 coronavirus. Aerus expects to receive clearances in all jurisdictions.
Additionally, Aerus is also running independent laboratory tests to demonstrate the efficacy of ActivePure Technology on airborne SARS-CoV-2 virus for FDA clearance.
ActivePure Technology is available in a wide range of products, both portable and installed, and is sold by a limited number of companies including Aerus, Aerus Enterprise Solutions (AES) and Vollara.
For more information on the efficacy of ActivePure Technology, go to ActivePure.com/covid.